Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of GDC-0853 in systemic lupus erythematosus
2016-001039-11Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fenebrutinib in systemic lupus erythematosus (SLE), sponsored by Genentech. Started Aug 2016; status: completed.
02
Drugs
fenebrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-001039-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001039-11.